StocksMediumUpdated•Originally published 4 November 2026•Updated 5 November 2026•
1 min read
Progyny Reports Record Q3 Results and Raises Full-Year 2026 Guidance
Key Facts
1Progyny achieved record revenue, net income, and Adjusted EBITDA during the third quarter.
2The company added 1.3 million new covered lives during its latest selling season, its highest ever.
3The company raised the midpoint of its full-year 2026 financial guidance ranges.
Progyny reported record third-quarter 2026 revenue of $341.3 million, exceeding analyst expectations. The company stated via GlobeNewswire that non-GAAP profit reached $0.52 per share, beating estimates by 2.2%, while adding a record 1.3 million new covered lives during its latest selling season.
PGNY closed at $29.06 on November 3, 2026, as results showed the fertility services client base grew to 607 clients by September 30, 2026, up from 553 in the prior year. Management guided for fourth-quarter 2026 revenue of approximately $354.7 million, leading to an upward revision of the midpoint for its full-year financial guidance.